Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations

US8877938B2 · kind B2 · utility

Assignee

• Novartis Pharmaceuticals Corporation · US

Inventors

• Lili Feng · Pine Brook, US
• Sven Erik Godtfredsen · Chatham, US
• Bin Hu · Mesa, US
• Yugang Liu · Bound Brook, US
• Piotr H. Karpinski · Lincoln Park, US
• Paul Allen Sutton · Parsippany, US
• Mahavir Prashad · East Hanover, US
• Michael John Girgis · Richmond, US
• Thomas J. Blacklock · Clark, US

Key dates

• Filing date: Nov 8, 2006
• Grant date: Nov 4, 2014
• Expiry date: May 27, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.